MétaCan
Menu
Back to cohort
Record W4225273794 · doi:10.21203/rs.3.rs-1600797/v1

Clinical and non-clinical exploration of Thinqure20 (a herbal composition) in treatment and prophylaxis of novel coronavirus and in other pathogens.

2022· preprint· en· W4225273794 on OpenAlexaff
Milind Gharpure, Hrishikesh ranganekar, Pranjali Dhawal, Ravindra Mote, Ravindra Gulgule, Nikhil, Sanjay vekariya

Bibliographic record

VenueResearch Square · 2022
Typepreprint
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicPiperaceae Chemical and Biological Studies
Canadian institutionsQuest University Canada
Fundersnot available
KeywordsTolerabilityMedicineAdverse effectClinical trialViral loadPharmacologyCoronavirus disease 2019 (COVID-19)CoronavirusInternal medicineVirusImmunologyInfectious disease (medical specialty)Disease

Abstract

fetched live from OpenAlex

Abstract Objective Ongoing pandemic is being tackled by many in many ways. Simple yet effective age-old formulations might hold a key in better management of the disease. Objective was to run a series of studies to make and explore one such formulation through reverse-pharmacology. Thinqure 20 is a polyherbal formulation that contains Piper longum, Piper nigrum, Zingiber officinale , and rock salt. Thinqure20 was designed to work as an antiviral drug, especially against SARS CoV-2 virus. Hence the present Clinical and subsequent non-clinical studies were carried-out to evaluate efficacy, safety and tolerability of Thinqure 20 in Covid-19 infection. Methods Clinical study was conducted to evaluate safety, efficacy and tolerability of Thinqure 20 in Covid-19 patients (CTRI/2021/03/032471). The treatment duration was 5 days. Patients were assessed for efficacy, safety, and tolerability of Thinqure20. Subsequently, non-clinical in-vitro cell line study, antiviral and antifungal, COVID SPIKE ACE2 inhibition studies were done on Thinqure20 extract. ASTM guidelines were followed for the same. Results The clinical study showed the mean percentage reduction in the viral load from baseline to end of the study visit of Thinqure 20 to be 75.4%, where the minimum reduction was 59.3%, while the maximum reduction in viral load was 100%. There were 04 clinical adverse events reported which were mild in nature. Viral load testing was done by Quantitative RT-qPCR for SARS-CoV-2 (Covid-19) RNA method from NABL accredited lab. A total of 30 patients were enrolled in the study. 29 patients completed the study. In the invitro study on cell-line, the extract showed potential antiviral activity against MS2 bacteriophage, a non-enveloped virus, influenza virus, and human coronavirus with IC90 value at > 10mg/ml. The sample also presented antifungal ability against Mucor racemosus with EC50 value at concentration 1mg/ml. Thinqure 20 was tested for its ACE2 receptor inhibitory activity. ). The kit-based SARS inhibitor showed 89.00% ACE 2 receptor inhibition when used as per KIT’s instructions. Conclusion The results showed that Thinqure 20 has potential against non-enveloped viruses and enveloped viruses including human coronavirus. It also showed antifungal activity against mucor strain. Evidences support that the use of Thinqure 20 has beneficial effects in the treatment of Covid19 which may be linked to a decrease in total viral load in patients. It provided better relief for the recovery of the COVID-19 disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.026
Threshold uncertainty score0.827

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.567
GPT teacher head0.595
Teacher spread0.028 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueResearch SquareSame topicPiperaceae Chemical and Biological StudiesFrench-language works237,207